Sodium-glucose co-transporter inhibition in the treatment of diabetes: Sweetening the pot

被引：3
作者：
Alvarez, Carlos A. [1 ,2 ]
Neeland, Ian J. [3 ]
McGuire, Darren K. [2 ,3 ]
机构：
[1] Texas Tech Univ, Hlth Sci Ctr, Dept Pharm Practice, Dallas, TX USA
[2] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Div Cardiol, Dallas, TX 75390 USA
来源：
DIABETES & VASCULAR DISEASE RESEARCH | 2015年 / 12卷 / 02期
关键词：
MYOCARDIAL-INFARCTION; VASCULAR COMPLICATIONS; CARDIOVASCULAR EVENTS; SGLT2; INHIBITORS; UNITED-STATES; DOUBLE-BLIND; TYPE-2; RISK; EFFICACY; ROSIGLITAZONE;
D O I：
10.1177/1479164114563303
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：74 / 77
页数：4
相关论文
共 29 条
[1]   Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes [J].
Abdul-Ghani, Muhammad A. ;
Norton, Luke ;
DeFronzo, Ralph A. .
ENDOCRINE REVIEWS, 2011, 32 (04) :515-531
[2]  
[Anonymous], NEW ENGL J MED
[3]   Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial [J].
Barnett, Anthony H. ;
Mithal, Ambrish ;
Manassie, Jenny ;
Jones, Russell ;
Rattunde, Henning ;
Woerle, Hans J. ;
Broedl, Uli C. .
LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05) :369-384
[4]   Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial [J].
Cefalu, William T. ;
Leiter, Lawrence A. ;
Yoon, Kun-Ho ;
Arias, Pablo ;
Niskanen, Leo ;
Xie, John ;
Balis, Dainius A. ;
Canovatchel, William ;
Meininger, Gary .
LANCET, 2013, 382 (9896) :941-950
[5]   Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006 [J].
Cheung, Bernard M. Y. ;
Ong, Kwok Leung ;
Cherny, Stacey S. ;
Sham, Pak-Chung ;
Tso, Annette W. K. ;
Lam, Karen S. L. .
AMERICAN JOURNAL OF MEDICINE, 2009, 122 (05) :443-453
[6]   Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes [J].
Duckworth, William ;
Abraira, Carlos ;
Moritz, Thomas ;
Reda, Domenic ;
Emanuele, Nicholas ;
Reaven, Peter D. ;
Zieve, Franklin J. ;
Marks, Jennifer ;
Davis, Stephen N. ;
Hayward, Rodney ;
Warren, Stuart R. ;
Goldman, Steven ;
McCarren, Madeline ;
Vitek, Mary Ellen ;
Henderson, William G. ;
Huang, Grant D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (02) :129-U62
[7]   Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin [J].
Edwards, Krystal L. ;
Alvarez, Carlos ;
Irons, Brian K. ;
Fields, Jessica .
PHARMACOTHERAPY, 2008, 28 (04) :506-521
[8]   Phlorizin: a review [J].
Ehrenkranz, JRL ;
Lewis, NG ;
Kahn, CR ;
Roth, J .
DIABETES-METABOLISM RESEARCH AND REVIEWS, 2005, 21 (01) :31-38
[9]   Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models [J].
Fujimori, Yoshikazu ;
Katsuno, Kenji ;
Nakashima, Ikumi ;
Ishikawa-Takemura, Yukiko ;
Fujikura, Hideki ;
Isaji, Masayuki .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (01) :268-276
[10]   Prevalence and Incidence Trends for Diagnosed Diabetes Among Adults Aged 20 to 79 Years, United States, 1980-2012 [J].
Geiss, Linda S. ;
Wang, Jing ;
Cheng, Yiling J. ;
Thompson, Theodore J. ;
Barker, Lawrence ;
Li, Yanfeng ;
Albright, Ann L. ;
Gregg, Edward W. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (12) :1218-1226
123